ArticleScientific reports2017
[
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- A scalable outpatient framework for BI-RADS 2-4B breast nodule management: an iodine-DMSO transdermal protocol.Frontiers in health services · 2026Pooled it
- Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.Blood advances · 2022Trial
- Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden.Research square · 2026Article
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
- [Future oncology (London, England) · 2025Article
- Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential.The Journal of pathology · 2025Article
- Recent developments in translational imaging of in vivo gene therapy outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Gene editing enables non-invasiveMolecular therapy. Methods & clinical development · 2025Article
- [18F]Tetrafluoroborate, a new NIS PET/CT radiopharmaceutical: an overview focused on differentiated thyroid cancer.European thyroid journal · 2025Review
- Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.Current radiopharmaceuticals · 2025Review
- Nuclear-Based Labeling of Cellular Immunotherapies: A Simple Protocol for Preclinical Use.Molecular imaging and biology · 2024Article
- Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer.Cancers · 2024Review
- Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.Current issues in molecular biology · 2023Review
- Positron emission tomography imaging of the sodium iodide symporter senses real-time energy stress in vivo.Cancer & metabolism · 2023Article
- Nanotechnology-Aided Advancement in Combating the Cancer Metastasis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) withMolecules (Basel, Switzerland) · 2023Article
- Spatiotemporal quantitative microRNA-155 imaging reports immune-mediated changes in a triple-negative breast cancer model.Frontiers in immunology · 2023Article
- Molecular imaging of cellular immunotherapies in experimental and therapeutic settings.Cancer immunology, immunotherapy : CII · 2022Review
- The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy.EJNMMI research · 2022Review
- A Human-derived Dual MRI/PET Reporter Gene System with High Translational Potential for Cell Tracking.Molecular imaging and biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Cancer cell metastasis is responsible for most cancer deaths. Non-invasive in vivo cancer cell tracking in spontaneously metastasizing tumor models still poses a challenge requiring highest sensitivity and excellent contrast. The goal of this study was to evaluate if the recently introduced PET radiotracer [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.